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A B S T R A C T
Obesity is a global health problem, most of which can probably be improved by changing dietary habits, 
with less consumption of processed and preserved foods and by increasing physical activity to combat the 
various hormonal imbalances that have developed in many individuals. Among the factors responsible 
for, or observed in, endocrine hypertension, are excessive increases in the action of hormones, including, 
aldosterone, mineralocorticoids, cortisol, and catecholamines (or by their action through the sympathetic 
nervous system), growth hormone, thyroid hormone, and parathyroid hormone. On the other hand, insulin 
resistance and deficiency of growth hormone, testosterone, vitamin D, and thyroid hormone may also be 
seen to contribute in patients with endocrine hypertension. A review is presented of recent advances in 
the traditional adrenal causes of endocrine hypertension and some non-traditional aspects of endocrine 
hypertension are illustrated, including our hypothesis that addiction to food, sweets, and salt are the main 
issues in many societies, and should be approached holistically and by the ancient philosophical method 
that a healthy mind will lead to a healthy body.
© 2012 Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo. Publicado por Elsevier España, S.L. 
Todos os direitos reservados.
Hipertensão endócrina: o que há de novo?
R E S U M O
A Obesidade é um problema global de saúde publica que na maioria das vezes pode ser melhorado com 
a mudança nos hábitos alimentares, diminuindo o consumo de alimentos processados e aumentando a 
actividade física como forma de combater os diferentes desequilíbrios hormonais que podem surgir 
em muitos  indivíduos. Entre os factores causadores ou concomitantemente observados na hipertensão 
endócrina inclui-se um aumento na actividade hormonal, como por exemplo, da aldosterona, dos 
mineralocorticóides, do  cortisol, das catecolaminas (ou pela sua acção através do sistema nervoso 
simpático) e as hormonas do crescimento, da tiróide e da paratiróide. Por outro lado, a insulino-resistência, 
a deficiência na hormona do crescimento, a testosterona, a Vitamina D e as hormonas da tiróide podem 
também contribuir para a hipertensão endócrina. Neste trabalho apresenta-se uma revisão dos mais 
recentes avanços obtidos na já tradicional hipertensão endócrina de causa suprarrenal e são ainda 
indicados outros aspectos menos referidos desta hipertensão, como por exemplo a nossa hipótese de que a 
dependência da comida, de doces e de sal é um dos aspetos mais importantes em muitas sociedades e como 
tal devem ser abordados de forma holística e conforme o antigo pensamento filosófico de que uma mente 
sã levará a um corpo são.
© 2012 Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo. Published by Elsevier España, S.L. 
All rights reserved.
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Introduction
The 2012 report F as in Fat (Trust for America’s Health) clearly 
underscores how obesity threatens America’s future, mainly by an 
increase in obesity-related health care costs, including those for 
type 2 diabetes, coronary heart disease, stroke, and hypertension. 
In 2011, 69% of Mississippians were overweight or obese, leaving 
only 31% with normal body mass index (BMI), when defined as 
<27 kg/m2.1 Although the extent of obesity and type 2 diabetes 
is still lower in Europe, including Portugal, than in America, it is 
also rising (obesity in Portuguese adults: approx. 18%), especially 
in children (approx. 25% in Portugal).2 History and the last several 
decades have shown that the fundamental drivers of the obesity 
epidemic are changes in food supply and physical environment, both 
socioeconomically driven, and hard to change by an individualistic 
free-market approach to obesity prevention.3,4 As we now know, the 
BMI definition of obesity is not perfect when assessing the risk for 
developing type 2 diabetes, as it does not tell the body composition, 
i.e. lean and fat mass.5 It also does not assist in separating obese 
individuals with insulin resistance and an inf lammatory state 
from those with insulin sensitivity and/or no inflammatory state. 
This explains why obesity-associated hypertension is a complex 
entity that belongs to a form of endocrine hypertension, as in some 
patients, testosterone deficiency and growth hormone deficiency, 
as well as vitamin D deficiency, may coexist with obesity.6 In 
women with polycystic ovarian syndrome, it remains controversial 
whether associated hypertension is independent of obesity. On 
the other hand, elevated blood pressure related to the intake of 
oral contraceptives and postmenopausal hormone therapy can be 
reversed by stopping hormonal therapy. This review aims to provide 
an update on the classical forms of endocrine hypertension, as well 
as providing insights into the non-traditional, less thought of forms 
of hormonal causes involved in causing or being associated with 
high blood pressure.7
Syndromes of mineralocorticoid excess
Among this group of disorders causing hypertension (Figure 1), is 
primary aldosteronism (PA), the most common form of syndromes 
of mineralocorticoid excess, with an estimated prevalence of up to 
13% in patients with moderate to severe hypertension, and of up 
to 23% in patients with resistant hypertension.8 Of note; screening 
for PA should be limited to selected patient groups, as there 
presently are limited data linking such screening to improvement of 
quality of life, reduced morbidity or mortality.9
Conditions with low renin concentrations include:
•  Mineralocorticoid Excess
•  Primary aldosteronism
•  Hypercortisolism (Cushing’s syndrome)
•  Glucocorticoid / cortisol resistance (Chrousos syndrome)
Figure 1. Inherited endocrine condition related to mineralocorticoid excess (modified after8,10,11). The picture shows the molecular pathways involved in dysregulation of NaCl 
homeostasis located in the distal renal tubules. +: activation; − inhibition; AME: apparent mineralocorticoid excess; CUL 3: cullin 3; ENaC: epithelial sodium channel; GRA: 
 glucocorticoid-remediable aldosteronism; KLHL3: kelch-like 3; MR: mineralocorticoid receptor; Nedd4-2: ubiquitin-protein ligase; deubiquitylating enzyme Usp2-45; NHERF2: 
Na+/H+ exchange regulating factor 2; PDK1,2: 3-phosphoinositide-dependent kinases 1 and 2; PHA2: pseudohypoaldosteronism type 2; ROMK: renal outer medullary potassium 
channel; Sgk1: serum glucocorticoid kinase 1; WNK: with-no-lysine kinase 1,4; 14-3-3 proteins.
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•  Apparent mineralocorticoid excess syndrome 
•  Licorice or carbenoxolone in excess 
•  Congenital adrenal hyperplasia (11beta- and 17alpha-hydroxylase 
deficiencies)
•  11-Deoxycorticosterone (DOC), 18-hydroxy-DOC excess
•  Geller Syndrome
•  Familial hyperkalemic hypertension (Gordon’s syndrome)
•  Liddle’s syndrome
After the first report of curing hypertension and hypokalemia in 
a Polish patient by removing an adrenocortical adenoma in 1953,12 
major advances have been accomplished, namely improving our 
tools of measuring aldosterone, plasma renin activity (involves 
generating angiotensin from angiotensinogen, radioimmunoassay 
(not standardized among laboratories) or direct active renin 
(automated chemiluminescence immunoassay in Europe), of 
localization / imaging (adrenal vein sampling, computed or magnetic 
resonance tomography), and of medical or surgical therapy (with 
robotic assisted and/or laparoscopic adrenalectomy). Deciphering 
the human genome has helped identify several disease causing 
genes, including some being involved in primary aldosteronism, 
i.e. in the K-channel gene KCNJ5, encoding Kir3.4, a member of 
the inwardly rectifying K+ channel family. The presence of these 
mutations in the KCNJ5 gene alter the K+ conductance/ selectivity of 
this channel and consequently increase the Na+ conductivity 
(influx) with a further impact on voltage-gated calcium channels 
leading to cellular proliferation in the adrenal cortex.14 The recurrent 
somatic mutations (G151R, L168R) in the adrenal potassium 
channel KCNJ5 have been related to benign aldosterone-producing 
adenomas (APAs) with initial estimates reporting almost half of 
APAs being associated with these mutations.13-16 Subjects with the 
KCNJ5 G151E mutation have no features of APAs and hyperplasia, a 
different clinical course (not progressive) and excellent control of 
blood pressure with spironolactone.
We now know of familial aldosteronism type 1, type 2, and type 3, 
although the precise molecular pathogenesis of aldosteronomas 
still needs to be elucidated.17-19 Given the heterogeneity of tumors, 
not only between, but also within one individual, it may be more 
prudent to analyze family members with a known gene defect and 
identical tumors in a whole genome and exome wide sequencing 
project for targeted genes known to be involved in cell growth 
regulation. Some of these patients with familial aldosteronism 
(overall less than 5% of patients with PA) may require bilateral 
adrenalectomy to control their hypertension, which can occur at a 
young age (sometimes in childhood).
Despite all the advances in diagnosing and treating patients with 
primary aldosteronism over the last 60 years, it should be noted that 
approximately 30% of patients with primary aldosteronism have 
concurrent essential hypertension, which limits the surgical cure 
of hypertension, although biochemical cure of aldosterone excess 
occurs.20 Also, about 25% of patients with essential hypertension 
have low renin hypertension, emphasizing the need to evaluate 
patients with refractory hypertension, or those with an adrenal 
incidentaloma, by measuring the aldosterone and renin ratio, 
demonstrating aldosterone excess by a plasma aldosterone level 
that typically exceeds 15-20 ng/dl.21 The aldosterone to plasma 
renin activity ratio can be performed without posture stimulation 
and while the patient is taking antihypertensive drugs, except for 
mineralocorticoid receptor antagonists such as spironolactone 
and eplerenone, which should be discontinued at least 6 weeks 
prior to morning testing. Some authors recommend stopping 
beta-blockers 4 weeks before testing, as these drugs lower renin, 
and to a lesser extent, plasma aldosterone, thereby raising the 
aldosterone-renin ratio, with the resulting increase in false-positive 
tests. 18-Hydroxycorticosterone, a precursor of aldosterone has 
been controversially discussed as a marker for patients with 
aldosteronomas compared to patients with bilateral adrenal 
hyperplasia.21 18-hydroxycortisol and 18-oxocortisol are markedly 
increased in patients with familial aldosteronism type 3. The more 
sensitive biochemical and imaging tools have led to the detection 
of patients with normokalemic aldosteronism, and one should note 
that around 5% of all patients with hypertension have primary 
aldosteronism.21,22 Of note, plasma potassium is more reliable 
than serum potassium. A recent study showed that in patients 
with PA compared to those with essential hypertension, the 24 h 
urine sodium and potassium excretions are higher (150 mmol vs. 
105 mmol; 75 mmol vs. 30 mmol), underscoring that both patient 
groups would benefit from a salt restricted diet.23 Salt loading and 
aldosterone suppression testing for patients suspected of having 
primary aldosteronism is usually performed by obtaining a 24 h 
urine sodium excretion of more than 200 mmol,24 which should be 
an easy task considering the recent data from the Centers for Disease 
Control and Prevention, showing that 9 in 10 Americans consume 
more than 2.3 g of sodium daily, which corresponds to 100 mmol. 
This important fact illustrates how difficult it is to combat sodium 
intake and high blood pressure, as well as obesity, in various 
countries, especially when considering that many people no longer 
prepare fresh foods, but use preserved or processed food items.
Low renin hypertension in childhood can be caused by PA, 
apparent mineralocorticoid excess, 11-beta hydroxylase deficiency, 
or 17alpha-hydroxyalse deficiency (Table 1). Certain populations 
have an increased risk.8,25 Signs and symptoms in patients with 
11-beta hydroxylase deficiency are variable, and hypokalemia 
is infrequently observed. In the non-classic form, women may 
present with a clinical phenotype of polycystic ovarian syndrome. 
Patients with 17-alpha-hydroxylase deficiency are frequently Dutch 
Mennonites immigrated from Portugal and Spain, and as genotypic 
XY individuals may show genital ambiguity, sometimes with breast 
development during puberty, whereas no breast development is 
usually seen in XX individuals, often then referred to as sexual 
infantilism.26,27 In obese individuals, one could perhaps propose 
esterified and free estradiol in adipose tissue. Hypertension has now 
also become a problem in patients with 21-hydroxylase deficiency 
congenital adrenal hyperplasia, with elevated blood pressure 
and insulin resistance being more common in classic than in 
non-classic patients, and being associated with suppressed plasma 
renin activity in a cohort of 24 patients on chronic glucocorticoid 
therapy.28
In patients with Cushing’s syndrome, it still is very important 
to increase awareness of fellow colleagues to only use the lowest 
Table 1 
Main genes involved in syndromes of mineralocorticoid excess
Disease PA 11b-hydroxylase 
deficiency
17a-hydroxylase 
deficiency
Chrousos 
syndrome
AME Liddle syndrome PHA type 2 Geller syndrome
Gene candidate 
or 
location
KCNJ5
CYP11B1/CYPB2
7p22
CYP11B1 CYP17 GR 11B
HSD2
B-subunit 
SCNN1B/
g-subunit 
SCNN1G
WNK1,4
KLHL3
CUL3
SPAK
MCR
11b-HSD2: 11beta-hydroxysteroid dehydrogenase type 2; CUL 3: cullin 3; GR: glucocorticoid receptor; KLHL3: kelch-like 3; MCR: mineralocorticoid receptor; WNK: with-no-
lysine kinase 1,4.
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possible dose of any glucocorticoid needed to achieve a desired 
effect, while avoiding exogenous over-replacement effects, 
including those that increase blood pressure. This now may be 
made easier in patients with adrenal insufficiency on a novel 
hydrocortisone dual-release formulation, which has shown a 
reduced blood pressure, lower body weight, and improved glucose 
metabolism, compared to traditional thrice-daily conventional 
hydrocortisone tablets.29 The morbidity and mortality of patients 
with Cushing’s syndrome is mainly determined by the hypertension 
and type 2 diabetes / insulin resistance.30 This should certainly 
be kept in mind when discussing and exploring newer treatment 
options for patients with endogenous hypercortisolism. Among 
the contemporary adrenal suppressing agents ketoconazole, 
metyrapone, etomidate, mitotane, and aminogluthetimide, and 
newer agents such as the glucocorticoid receptor type 2 antagonist 
mifepristone and the somatostatin analog pasireotide have been 
recently approved.31-35 That hypertension is linked to subclinical 
Cushing’s syndrome has been controversially discussed, but will 
become increasingly important, similar to the emerging group of 
patients with adrenal or pituitary incidentalomas and subclinical / 
silent hypercortisolism or with silent pheochromocytoma.21,36-38 In 
this context, it is worthwhile thinking about a given hormone 
measurement, the effect at its receptor, and the distribution and 
density of such receptors in target tissues. This is exemplified 
by Chrousos syndrome or primary generalized or sporadic 
glucocorticoid resistance and hypersensitivity.39,40 Individuals 
with certain single nucleotide polymorphisms and/or mutations 
in the glucocorticoid receptor gene have a higher propensity for 
hypertension, insulin resistance, and obesity than those without 
such sequence variants.5
Pheochromocytoma
The prevalence and pretest probability of patients with 
pheochromocytoma are, in descending order: multiple endocrine 
neoplasia type 2 (approx. 50% of patients), von Hippel Lindau 
syndrome (26%), familial paraganglioma syndrome (20%), 
neurofibromatosis type 1 (<5%), adrenal incidentaloma (<10%), 
hypertension and suggestive symptoms (0.5%!), unselected 
hypertensives (0.2%!). Over the last 12 years, investigators have 
identif ied several new genes involved in the inheritance of 
pheochromocytoma and extra-adrenal paraganglioma.41-47 This 
has led to the detection of preclinical pheochromocytoma / 
paragangliomas by genetic testing of affected and at risk family 
members, with many of these patients being asymptomatic, raising 
the question of when one should surgically intervene, and with which 
type of surgery, as there are now laparoscopic transperitoneal and 
retroperitoneoscopic approaches for adrenal pheochromocytomas.48 
Asymptomatic patients with pheochromocytoma have previously 
been reported in 15 of 150 patients seen at the Mayo Clinic,49 and 
in 19 of 33 patients with adrenal pheochromocytomas that were 
incidentally discovered.50 Advances in the biochemical screening 
for pheochromocytoma include the addition of methoxytyramine for 
paragangliomas and the assessment of plasma free and urinary 
fractionated metanephrines by liquid chromatography, and tandem 
mass spectrometry.51,52 Table 2 shows test performance of plasma 
free and urinary fractionated metanephrines measured in various 
centers across the globe, where a negative test was defined as both 
metanephrine and normetanephrine within the reference range, 
and a positive test as either metanephrine or normetanephrine 
higher than the reference range.53
Among the newer genes and proteins is TMEM127, a negative 
regulator of mammalian target of rapamycin (mTOR) effector 
proteins.44,45 In patients with multiple endocrine neoplasia type 2, 
the molecular pathogenesis of pheochromocytomas includes 
germline mutations in the RET proto-oncogene.17,58-61
Patients with von Hippel Lindau (VHL)-associated pheochromo-
cytoma (approx. one third) often have silent tumors, and extra-
adrenal paragangliomas in up to 30%.37,62,63
These extra-adrenal pheochromocytomas or paragangliomas in 
patients with VHL disease can be sympathetic or parasympathetic 
and, if located in the head and neck, are mostly unable to pro-
duce and secrete catecholamines.62-64
In general, extra-adrenal pheochromocytomas have a higher 
frequency and potential of malignancy than pheochromocytomas 
located in the adrenal gland.65 Malignant pheochromocyto-
mas (defined as the presence of chromaffin tissue at locations where 
such tissue should not be present, i.e. lungs, liver, bone, lymph 
nodes) are uncommon in patients with VHL syndrome and Multiple 
endocrine neoplasia type 2 (MEN 2), with frequency rates less 
than 5%. Unfortunately, there are still no markers that can reliably 
distinguish a benign from a malignant pheochromocytoma, although 
germline mutations in the SDHB gene, PASS (pheochromocytoma of 
adrenal gland scaled score) >4, size and pheochromocytoma weight, 
Ki-67 index >4%, and lack of pS100 appear to be of prognostic 
value (see Figure 2 and Chapter 7 in the Endocrine Testing Protocol 
section, section editor: Christian A. Koch, by Eugen Melcescu & 
Christian A Koch 2012 at http://www.endotext.org/protocols/
protocols7/protocolsframe7.htm).
Determining the screening age for pheochromocytoma in 
VHL germline mutation carriers should depend on the potential 
beneficial and negative sequelae that could occur if screening were 
not performed, i.e. malignancy (lower than 5% in VHL disease !), 
hypertension, radiation exposure from frequent imaging tests. 
There is marked intrafamilial variation, and the penetrance of 
pheochromocytoma may be as late as age 54 years. At present, 
experts recommend that pheochromocytoma screening should 
be started in childhood, at the age of 8 years. The adrenal glands 
can be visualized while undergoing an MRI to look for renal 
abnormalities in patients with VHL disease. Approximately 40% of 
pheochromocytomas in children have an underlying hereditary 
cause with germline mutations in either the SDHx genes, RET 
proto-oncogene, VHL gene, or neurofibromatosis type 1 gene. More 
than 70% of pheochromocytomas presenting in children are due to 
VHL disease. The diagnosis can further be established by abdominal 
Table 2  
Sensitivity and specificity of plasma free and urinary metanephrines
Plasma free metanephrines Urinary metanephrines
Study Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
Mayo clinic  96  85 94 (t) 98 (t)
NIH  99  89 97 (f) / 77 (t) 69 (f) / 93 (t)
Vienna 100 100 - -
Perry et al.54 - - 97.1 91.1
Hickman et al.55 100  97.6 85.7 95.1
Grouzmann et al.56  96  89 95 86
Peaston et al.57 100  96 - -
F: fractionated; t: total metanephrines. 
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computed tomography and/or magnetic resonance imaging. 
Positron emission tomography should only be performed in patients 
with metastatic disease.
Given the low frequency rate of extra-adrenal pheochromo cyto-
mas (approx. 15%) and malignant pheochro mocytomas (< 5%) in 
patients with VHL disease, only selected patients should undergo 
123I-MIBG scanning to search for extra-adrenal or metastatic 
lesions, before adrenalectomy is performed. Some experts report 
a tumor size of larger than 5 cm, others of larger than 10 cm as 
trigger to perform 123I-MIBG imaging.21,48 Importantly, (isolated) 
pheochromocytoma can be the presenting manifestation of VHL 
syndrome. Approximately 50% of patients with apparently isolated 
familial pheochromocytoma have VHL disease and approximately 
10% of patients with apparently sporadic pheochromocytoma, 
acknowledging that a family history is not always present or reliably 
obtainable, and that even if VHL germline mutations were detected 
by certified laboratory testing in patients with non-syndromic pheo-
chromocytoma (i.e. in 3 of 182 patients), misdiagnoses can occur.66
A cost-effective panel of genetic prof iling by performing 
mutation analysis for the VHL, RET, SDHB, SDHD, TMEM127, MAX, 
SDHC, SDHA, SDHAF2 genes is debatable for all patients presenting 
with apparently sporadic pheochromocytoma, since up to 33% have 
germline mutations in the aforementioned genes.67
if >4× UNL (Plasma)
>2× UNL (Urine)
If positive diagnosis, check
for malignancy criteria
Positive
Positive
Negative
Clinical features of pheochromocytoma
Fractionated/free plasma and/or urine metanephrines
CT or MRI:
abd/pelvis or chest/head
Genetic testing if:
t1FEJBUSJDQBUJFOU
t1PTJUJWFGBNJMZIJTUPSZ
t#JMBUFSBMQIFPDISPNPDZUPNB
t4ZOESPNJDQIFPDISPNPDZUPNB
RET / NEB2A
VHL
NF1
SDHD
SDHAF2
SDHC
SDHB
SDHA
KIF1B
EGLN1a
TMEM127
MAX
Plasma chromogranin A
.FEJDBM4VSHJDBMGPMMPXVQ
Functional imaging:
[123/131]*PEJOF.*#(
speciﬁc PET ([18F]FDA, [18F]FDOPA)
OPOTQFDJmD1&5	[18F]FDG)
Octreoscan / or PET/CT
Malignancy criteria:
t5VNPSOFDSPTJT
t1"44
t,JJOEFY
tQ4BCTFODF
tSDHB
t.FUIPYZUZSBNJOF
Figure 2. Flow chart for diagnostic evaluation for Pheochromocytoma. Adapted after: Waguespack SG, et al. JCEM. 2010;95:2023-37, from Chapter 7, Melcescu & Koch. Testing 
for endocrine hypertension. In: De Groot L, editor. Available from: www.endotext.org, section: Christian A. Koch.
Whether non-functional pheochromocytomas in VHL patients 
(only clinically remarkable as adrenal masses on imaging with 
normal fractionated urinary metanephrines and/or normal plasma 
free metanephrines) require treatment/surgery, and if they are 
smaller than 5 cm, it remains unclear. Important aspects in this 
context are the questions such as; how fast do these tumors grow, if 
and when they cause symptoms, and if and when (at what size) they 
metastasize. 
The likelihood of malignancy among hereditary pheochromo-
cytoma syndromes when having a germline mutation seems to 
be in descending order in the following genes: SDHB, (MAX), NF1, 
(TMEM127), VHL, RET, SDHD. Therapy with sunitinib, a tyrosine 
kinase inhibitor of vascular endothelial growth factor, platelet 
derived growth factor, RET, c-KIT, and FLT-3 receptor, may be 
promising, when looking at a 21% tumor shrinkage (pelvic malignant 
pheochromocytoma) and reduction of plasma normetanephrine 
and chromogranin A after 6 months of therapy. Other experimental 
therapies include arsenic trioxide, radiolabelled somatostatin 
analogs, including Yttrium-90-DOTATOC (90Y-DOTA-TOC) and 
Lutetium-177-DOTA0-Tyr3-octreotate (177Lu-DOTA-TATE), 
the mTOR inhibitor everolimus (RAD001) in combination with 
octreotide, novel dual PI3k/mTOR inhibitor (NVP-BEZ235), and HIF1a 
inhibitors.46,68-71 After surgery (and 131I-MIBG therapy) for malignant 
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showed that hypothyroidism can raise blood pressure by volume 
expansion with low plasma renin levels.86-88 Typically, marked 
reduced sensitivity to sympathetic agonists, increasing peripheral 
vascular resistance, and arterial stiffness are observed in hypothyroid 
patients, whereas hyperdynamic circulation changes are seen in 
patients with hyperthyroidism.89 Beta-blockers are preferred for 
blood pressure control in hyperthyroid patients, whereas calcium 
channel blockers and diuretics, as well as a low sodium diet, often 
improve blood pressure in patients with hypothyroidism. Women 
with subclinical hypothyroidism identified during pregnancy are 
at increased risk for severe pre-eclampsia compared to euthyroid 
women.90 Increased cardiac output leads to a reduction in plasma 
renin activity and in peripheral vascular resistance, together with 
isolated systolic hypertension in hyperthyroid women.91
Neuroendocrinological considerations
Mineralocorticoid receptors (MR) apparently play a role in 
certain areas of the brain including, the (anterior) hypothalamus, 
hippocampus, nucleus ventromedialis hypothalami, nucleus 
ambiguus, nucleus tractus solitarii, locus ceruleus, area postrema, 
and anterior pituitary, influencing homeostatic control of blood 
pressure, sodium intake, water and electrolyte balance, and 
sympathetic activation of heart and kidneys.92,93 One of the 
mechanisms of intracerebral aldosterone / MR action leading to an 
increase in vascular resistance and sympathetic tone appears to be a 
reduction of baroreceptor discharge.94
Excessive MR activation can promote inflammation, fibrosis, 
and heart disease, as well as psychiatric illness including anxiety 
and depression through key modulators, such as the glucocorticoid 
receptor (GR) and 11b-hydroxysteroid dehydrogenases (11b-HSDs).95,96 
So-called neurosteroids, synthesized in the brain, are involved in 
complex interactions within and outside the brain.97,98 In addition, 
steroids also enter the brain from the peripheral circulation. Patients 
with chronic hypercortisolemia frequently have depression, which 
appears to be related to dopamine synthesis in certain brain 
areas.99-101 Dopamine plays an important role in addictive behaviors, 
including compulsive shopping, eating, sodium appetite, gambling, 
and hypersexuality.102-106 Enkephalin surges in an anteromedial 
quadrant of the dorsal neostriatum have recently been found to 
contribute to generating intense consumption of palatable food.107
The relationship between hormonal and neural pathways 
(hypothalamus; arcuate nucleus; ventromedial, dorsomedial, and 
paraventricular nucleus) that regulate energy homeostasis and body 
fat are well shown and reviewed in (6). Involved are glucagon-like 
peptide 1, neuropeptide Y, oxyntomodulin, proopiomelanocortin, 
pancreatic polypeptide, peptide YY, orexin, cholecystokinin, alpha-
melanocyte stimulating hormone, Agouti-related protein, cocaine- 
and amphetamine-regulated transcript, melanin-concentrating 
hormone, and others. There is obviously a complex imbalance 
between the hunger hormone ghrelin and various satiety hormones 
including glucagon-like peptide 1, peptide Y, cholecystokinin, 
amylin.108 Given the global explosion of fast food restaurants over the 
last several decades and the dramatic rise in obesity, especially since 
1990, it is worthwhile asking the question on whether fast food is 
addictive in addition to being unhealthy, with inorganic phosphate 
in food additives causing vascular damage.109-111
Taste perception
One of the fundamental senses in humans is the taste system, 
with each taste being represented in its own separate cortical field, 
making up the gustotopic map in the brain.112 Manipulating this 
fundamental taste system, for instance, by masking of unwanted 
pheochromocytoma, the most used and effective chemotherapy 
regimen still consists of a combination of cyclophosphamide, 
vincristine, and dacarbazine (Averbuch protocol).
Non-traditional hormone conditions linked to hypertension
Hormonal imbalances are now present in many communities 
and societies, with an increasing number of obese and insulin 
resistant individuals compared to decades ago. Obesity-associated 
hypertension is very complex as there are various forms of obesity, 
some without insulin resistance or without any inflammatory state. 
As the ancient Greeks, Romans, and Egyptians emphasized “mens 
sana in corpore sano” should be the motto for many people today. 
Unfortunately, only a few are still able to listen to their internal voice 
and body, and train both mind and body to be strong.
Inf lammatory conditions including some forms of obesity 
and type 2 diabetes can lower testosterone and growth hormone, 
leading to a decline in the lean body mass, and a further increase 
in fat body mass, thereby contributing to more stress and increased 
sympathetic nervous system activity, resting tachycardia, insulin 
resistance, and hypertension.72-77 Chronic stress can also reduce 
growth hormone levels, with subsequent loss of lean body mass 
and an increase in fat mass, with more predisposition to insulin 
resistance and the development of the metabolic syndrome 
including hypertension. While data on the relationship between 
growth hormone deficiency and hypertension are emerging, the 
link between growth hormone excess and hypertension is strong, 
with good evidence showing an improvement or resolution of 
hypertension after successful treatment of acromegalic patients.73,78 
Whether headaches in acromegalics are linked to hypertension 
or the GH excess alone, or bone sequelae from it, remains unclear. 
Many acromegalics presenting with headaches report improvement 
of their headaches after normalizing insulin-like growth factor 1 
levels. One should remember that mortality in acromegalics (and 
GH levels >2.5 ng) has been shown to be related to cardiovascular 
issues including, among others, hypertension, cardiomyopathy, and 
arrhythmias.
Testosterone deficiency has now been recognized as a problem, 
not only for sexual function and bone health, but also for glycemic 
control and cardiovascular health.79 Serum total testosterone levels, 
even when measured with the best assay (currently with liquid 
chromatography and mass spectroscopy) often do not correlate well 
with symptoms and signs, illustrating the challenge of assessing 
intra- and inter-individual testosterone activity. A total serum 
testosterone level of greater than 200 ng/dl has been shown to be 
beneficial for bone health and risk of osteoporosis, whereas there 
is a wide range for sexual function and glycemic control, with most 
authorities considering a cut-off of 350 ng/dl.72
Obese individuals also frequently are found to have low 25-hydroxy 
vitamin D (25-OHD) levels, with data showing an improve ment in 
cardiovascular blood flow and function, including blood pressure, 
after raising 25-OHD (80). In this context, it is important to remember 
that biologically active vitamin D helps resorb calcium better, with 
some investigators having concerns about increasing cardiovascular 
risk due to calcium intake. However, recent studies, including 
those with an intake of 1 g of calcium citrate demonstrated no such 
risk, but rather improved coronary blood flow.81-83 Patients with 
longstanding severe primary hyperparathyroidism frequently show 
calcifications of their coronary arteries, and several studies have 
linked primary hyperparathyroidism to hypertension. However, 
the data in this context, including studies on reversing high blood 
pressure by surgical treatment of primary hyperparathyroidism, are 
conflicting.84,85
Similarly, there are data for and against the role of hypo- and 
hyperthyroidism in blood pressure regulation. Recently, studies 
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taste, can lead to commercial gains.113 So-called diet drinks with 
less sugar content but ingredients such as non-nutritive sweeteners 
like aspartame can affect perceived taste.114 German researchers 
have recently shown that obese children (age 6 to 18 years) have 
less sensitive taste buds when undergoing a paper strip test with 
the taste qualities, sweet, sour, salty, bitter and umami (savory). In 
that study, obese children rated sweet samples consistently as less 
sweet than did the normal-weight children.115 A sixth basic taste 
component, one that helps to detect dietary fat, has recently been 
suggested for obese subjects. The lipid taste receptor apparently 
is less able to detect triolein and oleic acid due to the intake of 
orlistat, a lipase inhibitor and weight loss medication.116 Salt 
consumption and salt appetite play an important role in blood 
pressure regulation and hypertension. Sodium salts often are added 
for flavor enhancement (for instance, to block or mask unpleasant 
tastes such as bitterness in cheese), or for functional purposes (i.e., 
preservation of food that is not immediately consumed). As the 
perceived intensity of sodium chloride shows a wide inter-individual 
variation, which in part is explained by individual taste function, 
the general over-consumption of salt / sodium chloride is mainly 
related to hedonic behavior.117,118 Sex hormones appear to play a 
role in the salt preference of men and women, as we know from 
studies including children and throughout pregnancy.119,120 During 
pregnancy, total serum cortisol concentrations increase, ovaries 
and maternal decidua produce early rises in renin levels causing 
5-20 fold increases in plasma aldosterone levels in the third 
trimester.121 Further stimulation of aldosterone production occurs 
due to the increased estrogen and subsequent angiotensin II 
levels.122 Progesterone furthermore stimulates the production of 
another potent mineralocorticoid, deoxycorticosterone, which rises 
by 2-3 fold.123
Normal salt discrimination is important for blood pressure 
control, and is dependent on the taste receptor field origin, nerve 
transmission and respective circuit in the brain. Oral amiloride, an 
epithelial sodium channel blocker that is frequently used in patients 
with hypertension, can severely affect the discrimination between 
sodium chloride and potassium chloride taste in rats.124 Syndromes 
of mineralocorticoid excess typically result from overactive 
amiloride-sensitive sodium channels.8 These are located in the 
distal tubule and collecting ducts of the kidney, as well as other 
tissues, including vascular smooth muscle, sweat glands, and distal 
colon.125-128
In normotensive young men with a positive family history of 
arterial hypertension, salt loading with 5 g of sodium chloride 
daily for one week (which is far below the daily consumption of 
most Americans) did not result in an adequate suppression 
of aldosterone, likely increasing their risk of becoming hypertensive 
in the future if overconsumption of salt were continued, and if the 
central effects of aldosterone and stimulation of the MR were taken 
into account.92,129
Bitter taste receptors have the function to protect against 
ingestion of potentially toxic substances and belong to the G-protein 
coupled receptor superfamily.130 If cheese were less salted, it would 
taste more bitter, and would likely lead to less consumption of both 
salt and calories from cheese, and concomitantly consumed food 
items and/or alcohol (wine etc.). While the bitter taste is usually 
masked with increasing salt content, sour / acidic taste (commonly 
found in preservatives) is compensated by an admixture of 
sweeteners or sugar, thereby increasing the consumption of such 
products.131 The cephalic phase insulin release is characterized by 
insulin release before increasing plasma glucose levels by tasting 
sweet food. In Wistar rats, the non-nutritive sweetener saccharine 
can elicit this cephalic phase insulin release, but non-sweet 
starch, which is nutritive, cannot.132 In humans, diurnal variation 
of sweet taste recognition thresholds is correlated with plasma 
leptin levels, with the lowest thresholds in the morning and the 
highest thresholds at night in non-obese subjects.133 It would be 
interesting to know the sweet taste recognition thresholds of obese 
individuals with leptin resistance and often insulin resistance. 
Ghrelin, a 28-amino acid peptide hormone, stimulates the release 
of growth hormone, appetite, food-seeking behavior, and olfactory 
sensitivity, as well as inf luencing taste responsiveness, with 
plasma ghrelin levels being elevated before meals and reduced 
after eating.134 Data from ghrelin cognate receptor (GHSR) null mice 
that showed significantly reduced taste responsivity to sour (citric 
acid) and salty (sodium chloride) tastants, suggest that ghrelin, 
which is present within the taste buds of the tongue, plays a local 
modulatory role in taste bud signaling and function.135 In Dahl-Iwai 
salt-sensitive rats, continuous administration of the ghrelin 
receptor antagonist, [D-Lys³]-GHRP-6, can induce salt-sensitive 
hypertension, probably by increasing autonomic sympathetic 
nervous activity.136
Ghrelin plasma levels are decreased in obese individuals, unless 
Prader Willi syndrome is present, in which case circulating ghrelin 
levels are high.137 One could wonder how the physiology of ghrelin, 
satiety hormones, and hypothalamic functions in general (food 
intake, thirst perception, osmostat, reproductive behavior, etc.) 
could be manipulated to generate the perfect storm for obesity 
and its consequences, including hypertension with a variety of 
hedonic and addiction behaviors, perhaps facilitated by an evil 
cocktail of food additives and drugs, including antidepressive 
agents.138,139
Conclusion
In addition to obesity, type 2 diabetes, and metabolic syndrome, 
hypertension represents a major public and global health problem, 
most of which could probably be improved by lifestyle changes, 
including changing dietary habits with a lower consumption of 
the processed and preserved foods that generally contain higher 
amounts of salt than freshly preserved food items. A Cochrane 
Database systematic review in 2011 showed that sodium reduction 
reduced blood pressure by 1% in normotensives and by 3.5% in 
hypertensives.140 In addition, an increase in physical activity can 
improve overall health dramatically and certainly would help 
achieve the ancient Greek and Roman model “mens sana in corpore 
sano”.141 Endocrine hypertension is on the rise when considering 
non-traditional factors such as obesity-associated hypertension, 
testosterone, GH, and vitamin D deficiency and such like. The rare 
syndromes of mineralocorticoid excess are linked to overactive 
amiloride-sensitive sodium channels, and are becoming more 
common in an environment promoting sodium chloride intake. The 
treatment for most of these conditions consists of restricting dietary 
salt intake. In addition, some require special therapies including 
dexamethasone / hydrocortisone for patients with congenital 
adrenal hyperplasia, spironolactone / eplerenone for apparent 
mineralocorticoid excess, epithelial sodium channel inhibitors 
amiloride / triamterene for Liddle syndrome and for familial and 
sporadic hyperkalemic hypertension.
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